Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies
Mortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns of cause-specific mortality are evolving as the population with HIV ages. We aimed to investigate longitudinal trends in cause-specific mortality amo...
Uloženo v:
| Vydáno v: | The lancet HIV Ročník 11; číslo 3; s. e176 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Netherlands
01.03.2024
|
| Témata: | |
| ISSN: | 2352-3018, 2352-3018 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Mortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns of cause-specific mortality are evolving as the population with HIV ages. We aimed to investigate longitudinal trends in cause-specific mortality among people with HIV starting ART in Europe and North America.
In this collaborative observational cohort study, we used data from 17 European and North American HIV cohorts contributing data to the Antiretroviral Therapy Cohort Collaboration. We included data for people with HIV who started ART between 1996 and 2020 at the age of 16 years or older. Causes of death were classified into a single cause by both a clinician and an algorithm if International Classification of Diseases, Ninth Revision or Tenth Revision data were available, or independently by two clinicians. Disagreements were resolved through panel discussion. We used Poisson models to compare cause-specific mortality rates during the calendar periods 1996-99, 2000-03, 2004-07, 2008-11, 2012-15, and 2016-20, adjusted for time-updated age, CD4 count, and whether the individual was ART-naive at the start of each period.
Among 189 301 people with HIV included in this study, 16 832 (8·9%) deaths were recorded during 1 519 200 person-years of follow-up. 13 180 (78·3%) deaths were classified by cause: the most common causes were AIDS (4203 deaths; 25·0%), non-AIDS non-hepatitis malignancy (2311; 13·7%), and cardiovascular or heart-related (1403; 8·3%) mortality. The proportion of deaths due to AIDS declined from 49% during 1996-99 to 16% during 2016-20. Rates of all-cause mortality per 1000 person-years decreased from 16·8 deaths (95% CI 15·4-18·4) during 1996-99 to 7·9 deaths (7·6-8·2) during 2016-20. Rates of all-cause mortality declined with time: the average adjusted mortality rate ratio per calendar period was 0·85 (95% CI 0·84-0·86). Rates of cause-specific mortality also declined: the most pronounced reduction was for AIDS-related mortality (0·81; 0·79-0·83). There were also reductions in rates of cardiovascular-related (0·83, 0·79-0·87), liver-related (0·88, 0·84-0·93), non-AIDS infection-related (0·91, 0·86-0·96), non-AIDS-non-hepatocellular carcinoma malignancy-related (0·94, 0·90-0·97), and suicide or accident-related mortality (0·89, 0·82-0·95). Mortality rates among people who acquired HIV through injecting drug use increased in women (1·07, 1·00-1·14) and decreased slightly in men (0·96, 0·93-0·99).
Reductions of most major causes of death, particularly AIDS-related deaths among people with HIV on ART, were not seen for all subgroups. Interventions targeted at high-risk groups, substance use, and comorbidities might further increase life expectancy in people with HIV towards that in the general population.
US National Institute on Alcohol Abuse and Alcoholism. |
|---|---|
| AbstractList | Mortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns of cause-specific mortality are evolving as the population with HIV ages. We aimed to investigate longitudinal trends in cause-specific mortality among people with HIV starting ART in Europe and North America.
In this collaborative observational cohort study, we used data from 17 European and North American HIV cohorts contributing data to the Antiretroviral Therapy Cohort Collaboration. We included data for people with HIV who started ART between 1996 and 2020 at the age of 16 years or older. Causes of death were classified into a single cause by both a clinician and an algorithm if International Classification of Diseases, Ninth Revision or Tenth Revision data were available, or independently by two clinicians. Disagreements were resolved through panel discussion. We used Poisson models to compare cause-specific mortality rates during the calendar periods 1996-99, 2000-03, 2004-07, 2008-11, 2012-15, and 2016-20, adjusted for time-updated age, CD4 count, and whether the individual was ART-naive at the start of each period.
Among 189 301 people with HIV included in this study, 16 832 (8·9%) deaths were recorded during 1 519 200 person-years of follow-up. 13 180 (78·3%) deaths were classified by cause: the most common causes were AIDS (4203 deaths; 25·0%), non-AIDS non-hepatitis malignancy (2311; 13·7%), and cardiovascular or heart-related (1403; 8·3%) mortality. The proportion of deaths due to AIDS declined from 49% during 1996-99 to 16% during 2016-20. Rates of all-cause mortality per 1000 person-years decreased from 16·8 deaths (95% CI 15·4-18·4) during 1996-99 to 7·9 deaths (7·6-8·2) during 2016-20. Rates of all-cause mortality declined with time: the average adjusted mortality rate ratio per calendar period was 0·85 (95% CI 0·84-0·86). Rates of cause-specific mortality also declined: the most pronounced reduction was for AIDS-related mortality (0·81; 0·79-0·83). There were also reductions in rates of cardiovascular-related (0·83, 0·79-0·87), liver-related (0·88, 0·84-0·93), non-AIDS infection-related (0·91, 0·86-0·96), non-AIDS-non-hepatocellular carcinoma malignancy-related (0·94, 0·90-0·97), and suicide or accident-related mortality (0·89, 0·82-0·95). Mortality rates among people who acquired HIV through injecting drug use increased in women (1·07, 1·00-1·14) and decreased slightly in men (0·96, 0·93-0·99).
Reductions of most major causes of death, particularly AIDS-related deaths among people with HIV on ART, were not seen for all subgroups. Interventions targeted at high-risk groups, substance use, and comorbidities might further increase life expectancy in people with HIV towards that in the general population.
US National Institute on Alcohol Abuse and Alcoholism. Mortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns of cause-specific mortality are evolving as the population with HIV ages. We aimed to investigate longitudinal trends in cause-specific mortality among people with HIV starting ART in Europe and North America.BACKGROUNDMortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns of cause-specific mortality are evolving as the population with HIV ages. We aimed to investigate longitudinal trends in cause-specific mortality among people with HIV starting ART in Europe and North America.In this collaborative observational cohort study, we used data from 17 European and North American HIV cohorts contributing data to the Antiretroviral Therapy Cohort Collaboration. We included data for people with HIV who started ART between 1996 and 2020 at the age of 16 years or older. Causes of death were classified into a single cause by both a clinician and an algorithm if International Classification of Diseases, Ninth Revision or Tenth Revision data were available, or independently by two clinicians. Disagreements were resolved through panel discussion. We used Poisson models to compare cause-specific mortality rates during the calendar periods 1996-99, 2000-03, 2004-07, 2008-11, 2012-15, and 2016-20, adjusted for time-updated age, CD4 count, and whether the individual was ART-naive at the start of each period.METHODSIn this collaborative observational cohort study, we used data from 17 European and North American HIV cohorts contributing data to the Antiretroviral Therapy Cohort Collaboration. We included data for people with HIV who started ART between 1996 and 2020 at the age of 16 years or older. Causes of death were classified into a single cause by both a clinician and an algorithm if International Classification of Diseases, Ninth Revision or Tenth Revision data were available, or independently by two clinicians. Disagreements were resolved through panel discussion. We used Poisson models to compare cause-specific mortality rates during the calendar periods 1996-99, 2000-03, 2004-07, 2008-11, 2012-15, and 2016-20, adjusted for time-updated age, CD4 count, and whether the individual was ART-naive at the start of each period.Among 189 301 people with HIV included in this study, 16 832 (8·9%) deaths were recorded during 1 519 200 person-years of follow-up. 13 180 (78·3%) deaths were classified by cause: the most common causes were AIDS (4203 deaths; 25·0%), non-AIDS non-hepatitis malignancy (2311; 13·7%), and cardiovascular or heart-related (1403; 8·3%) mortality. The proportion of deaths due to AIDS declined from 49% during 1996-99 to 16% during 2016-20. Rates of all-cause mortality per 1000 person-years decreased from 16·8 deaths (95% CI 15·4-18·4) during 1996-99 to 7·9 deaths (7·6-8·2) during 2016-20. Rates of all-cause mortality declined with time: the average adjusted mortality rate ratio per calendar period was 0·85 (95% CI 0·84-0·86). Rates of cause-specific mortality also declined: the most pronounced reduction was for AIDS-related mortality (0·81; 0·79-0·83). There were also reductions in rates of cardiovascular-related (0·83, 0·79-0·87), liver-related (0·88, 0·84-0·93), non-AIDS infection-related (0·91, 0·86-0·96), non-AIDS-non-hepatocellular carcinoma malignancy-related (0·94, 0·90-0·97), and suicide or accident-related mortality (0·89, 0·82-0·95). Mortality rates among people who acquired HIV through injecting drug use increased in women (1·07, 1·00-1·14) and decreased slightly in men (0·96, 0·93-0·99).FINDINGSAmong 189 301 people with HIV included in this study, 16 832 (8·9%) deaths were recorded during 1 519 200 person-years of follow-up. 13 180 (78·3%) deaths were classified by cause: the most common causes were AIDS (4203 deaths; 25·0%), non-AIDS non-hepatitis malignancy (2311; 13·7%), and cardiovascular or heart-related (1403; 8·3%) mortality. The proportion of deaths due to AIDS declined from 49% during 1996-99 to 16% during 2016-20. Rates of all-cause mortality per 1000 person-years decreased from 16·8 deaths (95% CI 15·4-18·4) during 1996-99 to 7·9 deaths (7·6-8·2) during 2016-20. Rates of all-cause mortality declined with time: the average adjusted mortality rate ratio per calendar period was 0·85 (95% CI 0·84-0·86). Rates of cause-specific mortality also declined: the most pronounced reduction was for AIDS-related mortality (0·81; 0·79-0·83). There were also reductions in rates of cardiovascular-related (0·83, 0·79-0·87), liver-related (0·88, 0·84-0·93), non-AIDS infection-related (0·91, 0·86-0·96), non-AIDS-non-hepatocellular carcinoma malignancy-related (0·94, 0·90-0·97), and suicide or accident-related mortality (0·89, 0·82-0·95). Mortality rates among people who acquired HIV through injecting drug use increased in women (1·07, 1·00-1·14) and decreased slightly in men (0·96, 0·93-0·99).Reductions of most major causes of death, particularly AIDS-related deaths among people with HIV on ART, were not seen for all subgroups. Interventions targeted at high-risk groups, substance use, and comorbidities might further increase life expectancy in people with HIV towards that in the general population.INTERPRETATIONReductions of most major causes of death, particularly AIDS-related deaths among people with HIV on ART, were not seen for all subgroups. Interventions targeted at high-risk groups, substance use, and comorbidities might further increase life expectancy in people with HIV towards that in the general population.US National Institute on Alcohol Abuse and Alcoholism.FUNDINGUS National Institute on Alcohol Abuse and Alcoholism. |
| Author | Silverberg, Michael J Wyen, Christoph d'Arminio Monforte, Antonella Trickey, Adam Hessamfar, Mojgan Gill, M John Sterne, Jonathan A C Reiss, Peter Imaz, Arkaitz Guest, Jodie L Teira, Ramon Berenguer, Juan Crane, Heidi Kusejko, Katharina Grabar, Sophie McGinnis, Kathleen Ingle, Suzanne M Zangerle, Robert Abgrall, Sophie Sterling, Timothy R Papastamopoulos, Vasileios |
| Author_xml | – sequence: 1 givenname: Adam surname: Trickey fullname: Trickey, Adam email: adam.trickey@bristol.ac.uk organization: Population Health Sciences, University of Bristol, Bristol, UK. Electronic address: adam.trickey@bristol.ac.uk – sequence: 2 givenname: Kathleen surname: McGinnis fullname: McGinnis, Kathleen organization: VA Connecticut Healthcare System, West Haven, CT, USA – sequence: 3 givenname: M John surname: Gill fullname: Gill, M John organization: Department of Medicine, University of Calgary, South Alberta HIV Clinic, Calgary, AB, Canada – sequence: 4 givenname: Sophie surname: Abgrall fullname: Abgrall, Sophie organization: Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Béclère, Service de Médecine Interne, Clamart, France; APHP, Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP INSERM U1018, Le Kremlin-Bicêtre, France – sequence: 5 givenname: Juan surname: Berenguer fullname: Berenguer, Juan organization: Hospital General Universitario Gregorio Marañón, IiSGM, CIBERINFEC, Madrid, Spain – sequence: 6 givenname: Christoph surname: Wyen fullname: Wyen, Christoph organization: Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany – sequence: 7 givenname: Mojgan surname: Hessamfar fullname: Hessamfar, Mojgan organization: University of Bordeaux, ISPED, INSERM U1219, Bordeaux, France; Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France – sequence: 8 givenname: Peter surname: Reiss fullname: Reiss, Peter organization: Stichting HIV Monitoring, Amsterdam, Netherlands; Amsterdam UMC, University of Amsterdam, Global Health, Amsterdam, Netherlands; Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands – sequence: 9 givenname: Katharina surname: Kusejko fullname: Kusejko, Katharina organization: Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland – sequence: 10 givenname: Michael J surname: Silverberg fullname: Silverberg, Michael J organization: Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA – sequence: 11 givenname: Arkaitz surname: Imaz fullname: Imaz, Arkaitz organization: Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain – sequence: 12 givenname: Ramon surname: Teira fullname: Teira, Ramon organization: Servicio de Medicina Interna, Hospital Universitario de Sierrallana, Torrelavega, Spain – sequence: 13 givenname: Antonella surname: d'Arminio Monforte fullname: d'Arminio Monforte, Antonella organization: University of Milan, Clinic of Infectious and Tropical Diseases, Department of Health Sciences, Milan, Italy – sequence: 14 givenname: Robert surname: Zangerle fullname: Zangerle, Robert organization: Department of Dermatology, Venereology and Allergy, Medical University Innsbruck, Innsbruck, Austria – sequence: 15 givenname: Jodie L surname: Guest fullname: Guest, Jodie L organization: Atlanta VA Medical Center, Decatur, GA, USA; Rollins School of Public Health at Emory University, Atlanta, GA, USA – sequence: 16 givenname: Vasileios surname: Papastamopoulos fullname: Papastamopoulos, Vasileios organization: 5th Department of Internal Medicine & Infectious Diseases Unit, Evangelismos General Hospital, Athens, Greece – sequence: 17 givenname: Heidi surname: Crane fullname: Crane, Heidi organization: Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA – sequence: 18 givenname: Timothy R surname: Sterling fullname: Sterling, Timothy R organization: Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA – sequence: 19 givenname: Sophie surname: Grabar fullname: Grabar, Sophie organization: Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France; Department of Public Health, AP-HP, St Antoine hospital, Paris, France – sequence: 20 givenname: Suzanne M surname: Ingle fullname: Ingle, Suzanne M organization: Population Health Sciences, University of Bristol, Bristol, UK – sequence: 21 givenname: Jonathan A C surname: Sterne fullname: Sterne, Jonathan A C organization: Population Health Sciences, University of Bristol, Bristol, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK; Health Data Research UK South-West, Bristol, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38280393$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1uFDEQhC0URELII4D6GA4Ddnt-PNyiKJBIKzjwc131jtus0Yy92B5QnojXxCsC4tSt0lfVpX4qTkIMLMRzJV8pqfrXH1F32GipzCXql1LigA0-Emf_5JP_9lNxkfM3KaXqWtO1-EScaoNG6lGfiV-bGL76slofaIaSONgMPsBEa-YM0YFlKnugpXJAdp1Lhp--Krd3XyAGoFB84pLiD5-OCXtOdLg_RtysKR64Ahbex1QdVwsnPxG4FBdQ49hDiYAS5RsgmOI80y4mKr6m1rtT3FcX5GM3zs_EY0dz5ouHeS4-v735dH3bbD68u7u-2jRT13WlQTsY3Q_cd-zIuJ3tpSMkrfSg0Ml2YoMO26nXO8tGadUPenAdTcqQszTiubj8k3tI8fvKuWwXnyeu3QLHNW9xxFHJvtWqoi8e0HW3sN0ekl8o3W__Phd_A6gQgGU |
| CitedBy_id | crossref_primary_10_1016_S2352_3018_25_00043_8 crossref_primary_10_1016_S2352_3018_25_00047_5 crossref_primary_10_1016_j_jtho_2025_03_032 crossref_primary_10_1186_s12981_025_00758_0 crossref_primary_10_1007_s11904_025_00735_2 crossref_primary_10_1097_QAD_0000000000004169 crossref_primary_10_2196_63783 crossref_primary_10_1093_ofid_ofaf455 crossref_primary_10_1097_QAD_0000000000004208 crossref_primary_10_1007_s15006_025_5054_9 crossref_primary_10_1016_j_antiviral_2025_106216 crossref_primary_10_1016_j_jiph_2025_102783 crossref_primary_10_1097_ID9_0000000000000174 crossref_primary_10_1016_j_idc_2024_06_007 crossref_primary_10_1093_cid_ciae190 crossref_primary_10_1080_25787489_2025_2535352 crossref_primary_10_1111_acer_15522 crossref_primary_10_1097_QAD_0000000000003993 crossref_primary_10_1016_j_idnow_2024_104990 crossref_primary_10_1080_01459740_2025_2527097 crossref_primary_10_3390_medicina61081468 crossref_primary_10_1186_s12903_025_05993_5 crossref_primary_10_1093_cid_ciae228 crossref_primary_10_1097_QAD_0000000000004012 crossref_primary_10_1016_S2352_3018_25_00011_6 crossref_primary_10_1186_s40001_025_02753_7 crossref_primary_10_3390_cancers17132088 crossref_primary_10_1016_j_molmed_2025_08_003 crossref_primary_10_1111_hiv_70054 crossref_primary_10_1038_s41598_024_80289_2 crossref_primary_10_3390_pathogens14070715 crossref_primary_10_1016_j_chest_2025_03_022 crossref_primary_10_1097_QAD_0000000000003924 crossref_primary_10_7759_cureus_75039 crossref_primary_10_3389_fimmu_2025_1670423 crossref_primary_10_1016_j_eimc_2025_04_008 crossref_primary_10_3389_fonc_2025_1440105 crossref_primary_10_1038_s41467_025_59408_8 crossref_primary_10_3390_life14111367 crossref_primary_10_1080_17425255_2024_2401044 crossref_primary_10_1016_j_lansea_2025_100576 crossref_primary_10_1016_j_lanepe_2024_100989 crossref_primary_10_3389_fsoc_2024_1393607 crossref_primary_10_1016_S2352_3018_24_00345_X crossref_primary_10_1093_ofid_ofaf551 crossref_primary_10_1016_S2352_3018_23_00295_3 crossref_primary_10_1016_j_jhlto_2025_100238 crossref_primary_10_1186_s12981_025_00772_2 crossref_primary_10_1001_jama_2024_24543 crossref_primary_10_1016_j_jad_2025_119815 crossref_primary_10_1093_jncics_pkae118 crossref_primary_10_1002_jia2_26384 crossref_primary_10_17816_pmj42455_63 crossref_primary_10_1007_s10461_024_04592_9 crossref_primary_10_1016_S2352_3018_24_00277_7 crossref_primary_10_3390_ijms26178165 crossref_primary_10_1097_QAD_0000000000004063 crossref_primary_10_1186_s12889_025_23542_1 crossref_primary_10_22625_2072_6732_2025_17_3_5_12 crossref_primary_10_2989_16085906_2025_2477090 crossref_primary_10_1097_QAD_0000000000004158 crossref_primary_10_1093_cid_ciaf175 crossref_primary_10_1093_ofid_ofae333 crossref_primary_10_1007_s40266_024_01168_z crossref_primary_10_1177_13596535251349336 crossref_primary_10_3389_fimmu_2025_1555441 crossref_primary_10_1080_09540121_2024_2437693 crossref_primary_10_1007_s41669_025_00584_0 crossref_primary_10_1111_hiv_13731 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/S2352-3018(23)00272-2 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2352-3018 |
| ExternalDocumentID | 38280393 |
| Genre | Journal Article Observational Study |
| GeographicLocations | North America Europe |
| GeographicLocations_xml | – name: North America – name: Europe |
| GrantInformation | US National Institute on Alcohol Abuse and Alcoholism. |
| GrantInformation_xml | – fundername: NIAAA NIH HHS grantid: U24 AA020794 – fundername: NIAID NIH HHS grantid: R24 AI067039 – fundername: Wellcome Trust – fundername: NIAID NIH HHS grantid: P30 AI050410 – fundername: NIAAA NIH HHS grantid: U01 AA026230 – fundername: NIAID NIH HHS grantid: P30 AI110527 – fundername: NIAAA NIH HHS grantid: U01 AA026209 – fundername: NIAID NIH HHS grantid: P30 AI027757 – fundername: NIAAA NIH HHS grantid: U01 AA026224 |
| GroupedDBID | -RU .1- .FO 0R~ 1P~ 4.4 457 53G AAEDT AAEDW AALRI AAMRU AAQFI AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AGCQF AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP CGR CUY CVF EBS ECM EFKBS EIF EJD FDB HZ~ M41 NPM O9- OD- OO. ROL Z5R 7X8 |
| ID | FETCH-LOGICAL-c555t-2d78367e65efa8fbd60fa2a313712f04ce82f24c63bde81316737f5ac18afda92 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 84 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001194756800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2352-3018 |
| IngestDate | Mon Sep 29 02:09:32 EDT 2025 Mon Jul 21 02:03:17 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c555t-2d78367e65efa8fbd60fa2a313712f04ce82f24c63bde81316737f5ac18afda92 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | https://www.clinicalkey.es/playcontent/1-s2.0-S2352301823002722 |
| PMID | 38280393 |
| PQID | 2929106431 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2929106431 pubmed_primary_38280393 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-03-01 |
| PublicationDateYYYYMMDD | 2024-03-01 |
| PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | The lancet HIV |
| PublicationTitleAlternate | Lancet HIV |
| PublicationYear | 2024 |
| SSID | ssj0001548542 |
| Score | 2.5711517 |
| Snippet | Mortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns of... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | e176 |
| SubjectTerms | Acquired Immunodeficiency Syndrome Adolescent Adult Cause of Death Cohort Studies Europe - epidemiology Female HIV Infections - epidemiology Humans Male Neoplasms North America - epidemiology Risk Factors |
| Title | Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38280393 https://www.proquest.com/docview/2929106431 |
| Volume | 11 |
| WOSCitedRecordID | wos001194756800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS91AEF_aasFLtV9-VZlCD3pYfNndJPu8iEjFgj6EVnm3x2Q_wEtiX_IE_6L-m53ZRB89FAq95BCSTchMZn47Xz8hvpAW0aZCG4nBGWksjiT58UzmAUeIqLXRqVH4spxM7HQ6vh4Cbu1QVvlkE5Oh9o3jGPmRIj-esf_MTu5_SmaN4uzqQKHxUqxogjKs1eXULmMsBMfzxJ-jCGdI0mW7bOI5-v588kDpQ96fKan-DjSTwzlf_99X3RBvBqgJp71uvBUvQv1OvO7JJx_fi1-XDXMVLTzzYkGXamPhrgaHiza00ETwDA8h0RFBmtPRAodt4eLbLTQ1kEzIXnYck5jzCv18Al6iD_HTBR5SXgiGvBBwMwtwRTJ0DSjCkMeA8Icq8nOZtHfeQduXOH4QN-dff5xdyIG2Qbo8zzupPHeGlKHIQ0QbK1-MIiokAZWZiiPjglVRGVfoygebcSu-LmOOLrMYPY7VR_GqbuqwJcAQHIqFI40JhQmmwOgqXxEGiTZiVuG2-PwkgRn9FpzrwDo0i3a2lMG22OzFOLvv53fMtGVKrrHe-Ye7d8UafQ3TV519EiuRjELYE6vuobtr5_tJ3-g4ub76DdIt3zU |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Longitudinal+trends+in+causes+of+death+among+adults+with+HIV+on+antiretroviral+therapy+in+Europe+and+North+America+from+1996+to+2020%3A+a+collaboration+of+cohort+studies&rft.jtitle=The+lancet+HIV&rft.au=Trickey%2C+Adam&rft.au=McGinnis%2C+Kathleen&rft.au=Gill%2C+M+John&rft.au=Abgrall%2C+Sophie&rft.date=2024-03-01&rft.eissn=2352-3018&rft.volume=11&rft.issue=3&rft.spage=e176&rft_id=info:doi/10.1016%2FS2352-3018%2823%2900272-2&rft_id=info%3Apmid%2F38280393&rft_id=info%3Apmid%2F38280393&rft.externalDocID=38280393 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2352-3018&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2352-3018&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2352-3018&client=summon |